Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug’s efficacy or tolerance. We decided to conduct a prospective randomized trial (OPTIM-imatinib trial) to assess t...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson-Ansah, Hyacinthe, Maneglier, Benjamin, Huguet, Françoise, Legros, Laurence, Escoffre-Barbe, Martine, Gardembas, Martine, Cony-Makhoul, Pascale, Coiteux, Valérie, Sutton, Laurent, Abarah, Wajed, Pouaty, Camille, Pignon, Jean-Michel, Choufi, Bachra, Visanica, Sorin, Deau, Bénédicte, Morisset, Laure, Cayssials, Emilie, Molimard, Mathieu, Bouchet, Stéphane, Mahon, François-Xavier, Nicolini, Franck, Aegerter, Philippe, Cayuela, Jean-Michel, Delord, Marc, Bruzzoni-Giovanelli, Heriberto, Rousselot, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414005/
https://www.ncbi.nlm.nih.gov/pubmed/36015302
http://dx.doi.org/10.3390/pharmaceutics14081676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414005/
https://www.ncbi.nlm.nih.gov/pubmed/36015302
http://dx.doi.org/10.3390/pharmaceutics14081676

Ejemplares similares